Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

November 24, 2015 7:31 PM ET


Company Overview of Protagonist Therapeutics, Inc.

Company Overview

Protagonist Therapeutics, Inc., a biotechnology company, develops orally stable peptide therapeutics for drugs against inflammatory bowel diseases (IBD), irritable bowel syndrome disease related targets, and gastrointestinal diseases and disorders. The company offers IL-6, a peptide antagonist as anti-inflammatory agent; and novel hepcidin peptide mimetic for the treatment of iron overload related disorders. Its pipeline includes PTG-100, an a4ß7 integrin specific oral peptide antagonist for the treatment of IBDs; and IL-23, a receptor oral peptide antagonist for treatment of IBDs. Protagonist Therapeutics, Inc. was founded in 2001 and is headquartered in Milpitas, California with discovery ...

521 Cottonwood Drive

Suite 100

Milpitas, CA 95035-7404

United States

Founded in 2001



Key Executives for Protagonist Therapeutics, Inc.

Chief Executive Officer, President and Director
Founder and Vice President of Technology & Alliances
Chief Medical Officer
Senior Vice President of Corporate Development
Senior Director of Chemistry
Compensation as of Fiscal Year 2015.

Protagonist Therapeutics, Inc. Key Developments

Protagonist Therapeutics, Inc. Receives SBIR Funding for Oral II-23 Receptor Antagonists for Treatment of Inflammatory Bowel Diseases

Protagonist Therapeutics, Inc. announced receipt of a phase 1 Small Business Innovation Research (SBIR) Grant from the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health. This award, Number R43DK104445, will support research aimed at optimizing lead molecules in Protagonist's second pipeline program, focused on orally stable peptide antagonists of the interleukin-23 (IL-23) receptor as potential treatments for inflammatory bowel diseases (IBD). Protagonist's research has shown that orally stable, GI-restricted drugs discovered using the company's peptide technology platform is efficacious in rodent models of colitis. This award furthers the company's efforts to translate these proof-of-concept early research findings into a potential human therapeutic that is orally delivered at high drug levels in diseased intestinal tissue with very limited drug concentrations in systemic circulation.

Protagonist Therapeutics, Inc. Presents at BIO-Europe 2015, Nov-03-2015 10:45 AM

Protagonist Therapeutics, Inc. Presents at BIO-Europe 2015, Nov-03-2015 10:45 AM. Venue: Munich, Germany.

Protagonist Therapeutics Names Richard S. Shames, M.D. as Chief Medical Officer

Protagonist Therapeutics, Inc. announced the appointment of Richard S. Shames, M.D. as Chief Medical Officer. Dr. Shames, most recently Senior Vice President and CMO at Aldea Pharmaceuticals, joins Protagonist with over 25 years of experience in clinical medicine and the biotechnology/pharmaceutical industry.

Similar Private Companies By Industry

Company Name Region
Transplant Genomics, Inc. United States
Eve Biomedical, Inc. United States
Celvive, Inc. United States
Pasteuria Bioscience, Inc. United States
Beckman Coulter Genomics Inc. United States

Recent Private Companies Transactions

Private Placement
July 10, 2015

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Protagonist Therapeutics, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at